1. Home
  2. JXG vs PLYX Comparison

JXG vs PLYX Comparison

Compare JXG & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JX Luxventure Limited

JXG

JX Luxventure Limited

HOLD

Current Price

$6.65

Market Cap

103.6M

Sector

N/A

ML Signal

HOLD

Logo Polaryx Therapeutics Inc. Common Stock

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$2.09

Market Cap

112.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JXG
PLYX
Founded
N/A
2014
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.6M
112.7M
IPO Year
2012
2025

Fundamental Metrics

Financial Performance
Metric
JXG
PLYX
Price
$6.65
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
23.1K
52.2K
Earning Date
05-14-2026
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$1.85
52 Week High
$12.00
$9.18

Technical Indicators

Market Signals
Indicator
JXG
PLYX
Relative Strength Index (RSI) 30.44 49.61
Support Level $6.19 $2.03
Resistance Level $10.09 $2.39
Average True Range (ATR) 0.87 0.10
MACD -0.23 0.02
Stochastic Oscillator 2.76 60.66

Price Performance

Historical Comparison
JXG
PLYX

About JXG JX Luxventure Limited

JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: